Onabotulinumtoxin A

OnabotulinumtoxinA May Be Effective for Chronic Migraine With Medication Overuse

OnabotulinumtoxinA May Be Effective for Chronic Migraine With Medication Overuse

By

OnabotulinumtoxinA at 195 UI may be effective in reducing the number of headaches per month and medication intake in patients with chronic migraine and medication overuse.

OnabotulinumtoxinA Safer, More Effective for Headache Prevention Than Topiramate

OnabotulinumtoxinA Safer, More Effective for Headache Prevention Than Topiramate

By

This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.

OnabotulinumtoxinA May Reduce Headache Days in Chronic Migraine

OnabotulinumtoxinA May Reduce Headache Days in Chronic Migraine

By

Treating chronic migraine with onabotulinumtoxinA may reduce the number of headache days when administered according to the National Institute for Health and Care Excellence guidelines.

Predicting Response to Onabotulinumtoxin A in Chronic Migraine

Predicting Response to Onabotulinumtoxin A in Chronic Migraine

By

A year-long treatment with onabotulinumtoxin A may effectively and safely reduce the number of monthly headaches in individuals with chronic migraine, particularly in individuals with unilateral pain.

OnabotulinumtoxinA May Be Safe, Effective for Long-Term Headache Prevention in Chronic Migraine

OnabotulinumtoxinA May Be Safe, Effective for Long-Term Headache Prevention in Chronic Migraine

By

The use of onabotulinumtoxinA every 12 weeks over a 2-year period was found to be safe, and effective for headache prevention in patients with chronic migraine.

OnabotulinumtoxinA for Tension-Type Headache: Research vs Real-Life Settings

OnabotulinumtoxinA for Tension-Type Headache: Research vs Real-Life Settings

By

Despite its prevalence, tension-type headache is often complicated by overlapping symptoms and a weak understanding of tension-type headache etiology.

Factors Contributing to Improved Outcomes With OnabotulinumtoxinA for Chronic Migraine

Factors Contributing to Improved Outcomes With OnabotulinumtoxinA for Chronic Migraine

By

OnabotulinumtoxinA was shown to have a better outcome in patients with chronic migraine who start the treatment within 12 months of symptom onset.

Sign Up for Free e-Newsletters